Inclusion Criteria:

- Signed consent

- Histologically- or cytologically confirmed diagnosis of Stage IIIB or IV non-small
cell lung cancer.

- Failed no more than two prior chemotherapy regimens for Stage IIIB or IV non-small
cell lung cancer, including a platinum-containing regimen.

- Brain metastases permitted if subject has been treated with surgery and/or radiation
therapy more than 4 weeks prior to date of first dose and is stable for at least one
week off steroids.

- 18 years of age or older.

- Eastern Cooperative Oncology Group performance status of at least 2.

- Measurable disease according to RECIST.

- Adequate organ system function.

- Females may be eligible to enroll if they are of non-childbearing potential
(surgically sterile or post-menopausal)or are using appropriate contraception
methods.

Exclusion Criteria:

- Prior malignancy - unless disease-free for at least 3 years, or have had completely
resected non-melanomatous skin cancer or successfully treated in situ carcinoma.

- History or clinical evidence of central nervous system metastases or leptomeningeal
carcinomatosis, except for subjects with previously-treated CNS metastases, who are
asymptomatic, and have had no requirement for steroids or anti-seizure medication for
one week prior to first dose of study drug.

- Clinically significant gastrointestinal abnormalities.

- Presence of uncontrolled infection.

- Corrected QT interval greater than 480 msec.

- History of significant cardiovascular condition(s).

- Poorly controlled hypertension (systolic blood pressure of 140mmHG or greater or
diastolic blood pressure of 90mmHg or greater).

- History of cerebrovascular accident, pulmonary embolism, or insufficiently treated
deep venous thrombosis within the past 6 months prior to first dose of study drug.

- Major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer.

- Active bleeding or diathesis.

- Hemoptysis in excess of 2.5mL within 8 weeks of first dose of study drug.

- Serious and/or unstable pre-existing medical, psychiatric, or other condition that
could interfere with subject's safety, provision of informed consent, or compliance
with study procedures.

- Use of prohibited medications as defined in protocol.

- Use of an investigational agent, including an investigational anti-cancer agent
within 28 days, or 5 half-lives, whichever is longer, prior to first dose of study
drug.

- Prior use of any investigational or licensed anti-angiogenic agent, including
thalidomide and agents that target platelet-derived growth factor. Prior treatment
with bevacizumab or epidermal growth factor receptor tyrosine kinase inhibitors